Tags: Obesity, Health Diabetes, Chronic diseases, Medical intervention, Interventions, Partnerships, Care

Novo Nordisk’s previous diabetes scenarios have followed a classic approach inspired by Shell, examining how the world might develop in various directions depending on how different factors play out. ‘Diabetes 2020’ in 2003 had a broad social point of departure sketching out two different societies focusing either on the technological or the human possibilities at hand. ‘Diabetes towards 2025’ in 2006 followed the same logic and counterpoised a biomedical and a public health perspective. The framing was somewhat narrower and discussed changes in the actor landscape in healthcare. The ‘Diabetes towards 2030’ scenarios ‘Diabetes towards 2030’ zooms in even further and links pharmaceutical business models to the pandemic growth of obesity and chronic diseases, significant advances in the understanding of human behaviour and of biology, and the ability to improve health outcomes in populations with diabetes and other chronic conditions.

Diabetes-towards-2030.pdf